we care
«The Company of Decade - the Russian pharmaceutical products manufacturer»

Strategy

We strongly believe that our achievements depend on successful implementation of the Company Strategy. Our goal is to further strengthen our leading position in the Russian pharmaceutical market. The key elements of our strategy are as follows:

  • Promote our market-leading brands to drive sales growth and profitability. We intend to strengthen our market position in Russia by continuing to leverage our strong brand loyalty and brand awareness through effective sales and marketing of our market-leading brands. We will continue promoting these brands by introducing line extensions of trusted and established products, such as our well-known branded product ranges Pentalgin®, Codelac®, Complivit®, Arbidol® and Flucostat®. We will also continue to focus on promoting higher value added brands — Afobazol®, Neupomax®, Biosulin®, Rastan®.
  • Launch new pharmaceutical products in a timely manner to capture market share. We intend to maintain strong growth and capture market share by leveraging the brand loyalty and brand awareness of our market-leading brands to develop and launch new products in our Core Therapeutic Segments. We also intend to develop and launch new products in potential for our growth new therapeutic segment. Specifically, we intend to:
  • focus on the timely identification and development of new products, including the development of line-extensions of current brands;
  • focus on the timely identification and development of new products that complement our Core Therapeutic Segments and develop new products to penetrate new therapeutic areas;
  • launch these new pharmaceutical products in a timely manner to capture significant market share;
  • leverage our sales and marketing infrastructure to promote new product launches and achieve leading market positions for new branded products
  • Maintain our focus on cost control. Our focus and ability to control costs is an important element of both our operating and financial performance. We will continue to evaluate and respond to manufacturing and distribution cost inefficiencies. We also plan to further rationalize our manufacturing costs in order to keep gross profit margins by managing our product mix on the basis of the demand for our pharmaceutical products.
  • Expand our sales and marketing capabilities. Our sales team has more than doubled in the last two years. We also intend to promote further specialization of the Company sales force by therapeutic areas and expect our more specialized sales and marketing team to facilitate our increased calling efforts on medical practitioners, regional and national distributors and other customers. This measure will help to increase customer awareness of our product portfolio and drive further sales growth.
  • Grow through acquisitions and realize synergies. We intend to complement our organic growth through the assessment and use of acquisition opportunities, including opportunities for specific brands, trademarks and patents.
  • Cooperation with leading pharmaceutical companies. We intend to complement our organic growth through cooperation with leading pharmaceutical companies based on co-manufacturing or exclusive marketing and promotion of their most successful pharmaceutical products.
  • Exploit opportunities arising from government funding of healthcare. We believe that we are well positioned to benefit from potential changes in the Federal Reimbursement Programme (FRP), which are expected to increase the participation of local producers. We plan further participation in the FRP, namely in the Federal Programme for 7 costly diseases with our own products and Third Party Products (TPP), and in the ONLC Programme (Provision of Essential Pharmaceuticals Programme).

    In addition, we expect growth in sterilizing devices market, where, we believe our products to have a cost-competitive advantage.
Menu
Company profile Mission Strategy Achievments Corporate Governance Shareholder structure Social Policy Products Facilities Corporate film Reorganization Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
Corporate film
Markets information WAP version
Delayed according to exchanges regulations. RUSTOCKS.com
Company profile Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
© 2007–2013 All rights reserved.
Terms of use www.pharmstd.com